How has your erectile dysfunction caseload changed since PDE-5 inhibitors became commercially available?

Share this content:

When phosphodiesterase-5 (PDE-5) inhibitors became commercially available for treating erectile dysfunction (ED), it was speculated that urologists could see a big decline in the number of ED patients going to them for treatment because these patients could simply get a prescription for these oral agents from their primary care doctor.

It is conceivable, however, that the advent of PDE-5 inhibitors, which have received considerable publicity and have been heavily advertised to consumers, has raised awareness of ED such that more men are seeking treatment and discovering that PDE-5 inhibitors do not work for them, prompting them to go to urologists for other treatments.

Renal & Urology News would like to get an idea of how PDE-5 inhibitors might have affected urologists' ED caseload, so please take a few moments to answer the following poll question:


Please leave a comment below for further explanation on your choice.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters